RAPIDO

Preliminary results from a UK-wide audit of reversal agents for direct oral anticoagulant associated bleeding

Buka RJ¹, Pettitt M², Sutton DJ³, Doyle A⁴, Lowe G⁵, Perry R², Magill L², Alikhan R^{6,7}, HaemSTAR Collaborators, Nicolson PLR¹,²

- 1. Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
- 2. Birmingham Centre for Prospective and Observational Studies, University of Birmingham, Birmingham, UK
- 3. Staffordshire Thrombosis and Anticoagulation Centre, University Hospitals North Midlands NHS Trust, Stoke-on-Trent, UK
- 4. Haemostasis and Thrombosis Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK
- 5. Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 6. Haemophilia and Thrombosis Centre, University Hospital of Wales, Cardiff, UK
- 7. Cardiff University School of Medicine, Cardiff, UK



HaemSTAR

Birmingham Centre for

Observational and

Prospective Studies

Aim: Audit the use of reversal agents for DOAC-associated bleeding across the UK

Background

- Major bleeding is a frequent complication of anticoagulation with direct oral anticoagulants
- Reversal agents are available but there are limited data on their use across the UK and whether this use is appropriate
- Although there is compelling data supporting the notion that these therapies are physiologically active, data on true clinical benefit is extremely limited
- UK-wide, patient level data is required to understand the current use of these agents


Results






















Major haemorrhage





	N=837	%
Age (mean, SD)	79.0 (10.6)	
Male	487	58.2
Ethnicity: white	625	74.7
Comorbidities		
Atrial fibrillation	699	83.5
Cancer	120	14.3
Dementia	121	14.5
Falls	217	25.9
Heart failure	210	25.1
Ischaemic heart disease	195	23.3
Liver disease	58	6.9
Prior arterial thrombosis	246	29.4
Prior major bleeding	70	8.4
Prior venous thrombosis	154	18.4
Concurrent medications		
Antihypertensives	566	67.6
Antiplatelets	90	10.8
SSRI	89	10.6
_PPI	354	42.3
Anticoagulant		
Apixaban	448	53.5
Dabigatran	52	6.2
Edoxaban	77	9.2
Rivaroxaban	260	31.1
Anticoagulant dose		
Low dose	283	33.8
Standard	515	61.5
Loading dose	7	8.0
Other	32	3.8

Table 1. Demographic and clinical information




Figure 4. Timing of restarting anticoagulation

Dosing

High dose: 7 (14%) Low dose: 42 (86%)

Andexanet alfa

Idarucizumab

5g: 47 (100%) Second dose: 1 (1%)

PCC (beriplex and octaplex) Off-licence use

Recommended dose caps Beriplex 5,000, Octaplex 3,000 units 1% doses exceeded caps




Figure 2. Dosing of beriplex and octaplex. (A) Total dose (B) Dose per kg.




Figure 5. Time between events (hours)

Summary

- Large dataset of DOAC reversal with patient-level data
- 93% patients had major bleeding
- PCC dosing is heterogeneous and clinical outcomes are similar with beriplex and octaplex which are dosed differently
- 90 day mortality: 41%; 90 day incidence of thrombosis: 4%
- Median 4.3h from admission to reversal agent administration More data required on use of andexanet alfa and idarucizumab

Methods

Inclusion criteria:

• Age ≥ 18 years

• Between 1st October 2020 and July 31st 2023 (current data until Jan 31st 2022) Data is collected by HaemSTAR collaborators - doctors and allied health professionals

Administration of 4 factor prothrombin complex concentrate (PCC [beriplex or

RAPIDO is a UK-wide retrospective audit collecting data from routine patient records.

- Data is anonymised and entered into a secure, online REDCap database
- Data has been analysed in GraphPad Prism 9

octaplex], andexanet alfa or idarucizumab)

The audit was supported by funding from AstraZeneca UK Limited

Primary outcomes

- Proportion of patients treated with a reversal agent who had severe or life-threatening bleeding
- Proportion of patients treated with a reversal agent who received treatment in accordance with the dosing schedule laid out in the relevant SPC

Bleed sites (C) **(B) (A)** N=837 N = 432N=136 Liver Unknown Fracture Femoral artery Limb Retroperitoneal ■ Splenic Vaginal ☐ Ruptured AAA **Epistaxis** Urine Haemoptysis Thorax Intraabdominal Haematoma Cardiac Other Skin Intracereberal Subarachnoid Gastrointestinal Subdural Other Other

Figure 1. Anatomical sites of bleeding. (A) All patients (B) Sites of intracranial bleeds (C) Sites of "Other" bleeding.




Figure 3. Clinical outcomes. Kaplan-Meier analyses of (A) death by bleed site, (B) death due to bleeding by bleed site, and (C) incidence of thrombosis. ****P<0.0001 for significance of difference by log rank test.




Figure 6. Clinical outcomes with PCC (beriplex and octaplex). Kaplan-Meier analyses (A) all bleeds, (B) GI bleeds, (C) ICH. Ns: not significant for difference by log rank test

Want to contribute?



Email: richard.buka@nhs.net www.haemstar.org/RAPIDO https://redcap.link/rapido

Acknowledgements

This project is funded by AstraZeneca and HaemSTAR has also received funding for the project from The Dudley Leukaemia Appeal Fund.

Collaborators

Alexander Bashford, Karthik Basker, Gilda Bass, Laura Batey, Chithrangani Batugedara, Ala Bawazir, Sue Beach, Edward Belsham, Caroline Betts, Gopika Bhaskar, Rachael Biggart, Nuno Borges, Sara Boyce, Olivia Brooke, Stanley Broughton, Clare Brown, Michael Buckton, Richard J Buka, Tom Bull, Lorna Cain, Sedeshka Cakmak, Ipek Cakmak, Samantha Carrington, Daniel Castle, Dominique Chan-Lam, Tatiana Christmas Deborah Clark, Charlotte Claydon, Ayodeji Coker, Freya Collings, Amy Cooper, Francesca Crolla, Henry L Crosland, Kirsty Crozier, Nicola Curry, Annie Curtis, Olga Delacruz, Alison Delaney, Nicholas Denny, Ian Devanny, Saniya Dhawan, Suzanne Docherty, Maribeth Donaldson Francesca Doughty, Andrew Doyle, Samantha Drummond, Portia Eardley, Hugh Edwards, Mohamed Elhadi, Shereef Elmoamly, Astric Etherington, Karim Farheen, Dina Fathoala, Joanna Fawcett, Cliona Flanaghan, Rhian Fuge, Agata Gaertner, Hannah Giles, Girgis Girgis, Jessica Griffin, Sudarshan Gurung, La'ali Gutierrez, Cecilia Gyansah, Anthony Hackett, Elizabeth Hardiman, LayaHariharan, Emma Harris Aichelle Harrison, Nayeem Hasan, Aidan Haslam, Eman Hassan, Joanna Haughton, Joannes Hermans, Charlotte Hickman, Joshua Hinds Kelly Holton, Joanne Hoyle, Nathan Hutchinson-Jones, Jack Illingworth, Mishal iqbal, Nkemdirim Jacob, Laura James, Sheila Jen, Michae Joffe, Erith Jones, Benedict Jong, Angela Kanny, Mamatha Karanth, Sajida Kazi, Ron Kerr, Jahanzeb Khawaja, Milo Kmonicek, Amy Knott, leena Krishnan, Arka Kyaw, Grace Langford, Alex Langridge, Claire Lentaigne, Francesca, Leonforte, Sarah Lewis, Anand, Lokare, Kary ongmuir, Gillian Lowe, Pyae Lwin, Rhona Maclean, Ben MacLeod, Gihan Mahmoud, Tara Maisel, Stuart Mann, Claire Mapplebeck, Elizabeth. Marrinan, Jon Massie, Bernard D Maybury, Thomas Mayo, Graham W McIlroy, Anke Meess, Michelle Melly, Jerssy Mhike, Loredana Gabriela Mihailescu, Jayna Mistry, Amany Mohamed, Sarah Mohamed, Khatib Mohammad, Shivir Y Moosai, James Morgan, Kerry Morrison, Kat Moss Dina Osman, Hajer Oun, Andrew Page, Krushika Paleja, Athanasia Sinti Papadaki, Katrina Parsons, Aran Patel, Kumari Perera, Matthev Powell, Mary Preston, Indu Punchihewa, Florije Raka, Himabindu Rebbapragada, Udaya Reddy, James WE Riley, Lara Roberts, Patrick Roberts, Philip Robson, Ryan Rodgers, Daniel W Rogalsky, Lucy Rose, Victoria Rowson, Jackie Ruell, Walaa Saad, Malahat Saeed, Fady Samy, Rebecca Sarsam, Hayley Scott, Moncef Seddiki, Fatima Shakkak , Rebecca Shaw, Julia Sillito, David Simcox, David Sparksman Phillippa Stimpson, David Sutton, David Sutton, Nadia Taha, Juan Tan, Myuri Thanabalasingam, Angela Theodoulou, Kirstie Thorneycroft, Molly 「horpe, Ellen Tiffin, Sophie Todd, Nuthan Tom, Nomathamsanga Tshuma, Olga Tsiamita, Mevish Ul-haq, Indrani Venkatadasari, Nataliia /ilinska, Mairi Walker, Sai Lon Wann, Vicki Ware, Lucy Watkins, George Watkinson, Carys Watson, Anna Wenham, Sarah Wheeldon, Katie White, Richard Whitmill, Charlotte Wild, Emma Williams, Julia Wolf, Hui Wong, Eleanor Wong, Rachel Wright, Yassin, Than Zaw